Enlivex Therapeutics to Host Investor Webinar
Ticker: ENLV · Form: 6-K · Filed: Jun 20, 2024 · CIK: 1596812
Sentiment: neutral
Topics: investor-relations, webinar, company-update
Related Tickers: ENLX
TL;DR
Enlivex hosting investor webinar June 25th - tune in for updates.
AI Summary
Enlivex Therapeutics Ltd. announced on June 20, 2024, that it will host an investor webinar on June 25, 2024, at 4:15 p.m. ET. The webinar will provide an update on the company's progress and strategic initiatives. This announcement was made via a press release furnished as part of their 6-K filing.
Why It Matters
This webinar provides an opportunity for investors to directly hear from Enlivex Therapeutics about their latest developments and future plans, potentially influencing investment decisions.
Risk Assessment
Risk Level: low — This filing is an announcement of a routine investor event and does not contain significant financial or operational news.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- June 25, 2024 (date) — Webinar date
- 4:15 p.m. ET (time) — Webinar time
FAQ
What is the purpose of the investor webinar?
The webinar is intended to provide investors with an update on Enlivex Therapeutics' progress and strategic initiatives.
When will the investor webinar take place?
The investor webinar is scheduled for June 25, 2024, at 4:15 p.m. ET.
What form was used to submit this information to the SEC?
This information was submitted on a Form 6-K.
What is Enlivex Therapeutics Ltd.'s principal executive office address?
The principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel 7403618.
Has Enlivex Therapeutics Ltd. previously operated under a different name?
Yes, the company was formerly known as Bioblast Pharma Ltd., with name changes recorded in 2014 and 2016.
Filing Stats: 213 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2024-06-20 08:04:56
Filing Documents
- ea0208130-6k_enlivex.htm (6-K) — 9KB
- ea020813001ex99-1_enlivex.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-054018.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: June 20, 2024 2